Literature DB >> 31604368

Purging with chlorambucil to prevent infusion-related reaction before obinutuzumab administration: A monocentric pilot experience.

Francesco Autore1, Alberto Fresa2, Idanna Innocenti1, Annamaria Tomasso2, Francesca Morelli2, Andrea Corbingi2, Federica Sorà1, Luca Laurenti1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31604368     DOI： 10.1002/hon.2684

Source DB:  PubMed          Journal:  Hematol Oncol        ISSN： 0278-0232            Impact factor:   5.271


× No keyword cloud information.
  2 in total

1.  Bone marrow involvement is a risk factor for infusion-related reactions in patients with follicular lymphoma treated by obinutuzumab.

Authors:  Yosuke Masamoto; Kazuki Taoka; Hiroaki Maki; Mineo Kurokawa
Journal:  Ann Hematol       Date:  2022-10-03       Impact factor: 4.030

2.  Real world risk of infusion reactions and effectiveness of front-line obinutuzumab plus chlorambucil compared with other frontline treatments for chronic lymphocytic leukemia.

Authors:  Nicole Bourrier; Ivan Landego; Oliver Bucher; Mandy Squires; Erin Streu; Irena Hibbert; Theresa Whiteside; Spencer B Gibson; Marc Geirnaert; James B Johnston; David E Dawe; Versha Banerji
Journal:  BMC Cancer       Date:  2022-02-06       Impact factor: 4.430
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.